ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Estimating cost savings from reducing antibiotic overprescription in european general practices.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotic (ATB) overprescription leads to antimicrobial resistance (AMR) and adverse events (AEs) and poses significant economic burdens on European healthcare systems. The aim of this study was to assess the economic impact associated with interventions aimed at reducing unnecessary ATB prescriptions in general practice, and to extrapolate the results at the European Union (EU) level.
methodsWe used data from the “HAPPY PATIENT” project, a before-and-after study that implemented a multifaceted intervention in primary care settings in France, Greece, Lithuania, Poland, and Spain. Based on the outcomes observed in general practice across these five countries we extrapolated the results to estimate for each of the 27 EU member states: i) the costs of implementing the interventions, ii) the number of potentially unnecessary ATB prescriptions avoided, and iii) the potential savings due to reductions in unnecessary ATB prescriptions. We considered a realistic and an optimistic scenario: using the mean and the largest reduction in unnecessary ATB prescriptions observed across each of the five participating countries, respectively.
resultsAcross the EU, €2.7 billion are estimated to be spent annually on healthcare resources linked to potentially unnecessary ATB prescribed in general practice. Implementing the interventions across the EU is projected to cost €107 million. Positive net savings were estimated in both scenarios, €151 million in the realistic scenario and €423 million in the optimistic scenario. Several sensitivity analyses were conducted to characterise the substantial uncertainty surrounding these estimates, which yielded considerable potential savings in all cases.
Indexed as
Identifiers
41862746What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.